() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: PRVCF

PreveCeutical Secures $300,000 Loan and Resignation of a Director

June 3, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has received a loan in the aggregate amount of $300,000 (the “Loan”) pursuant to a loan agreement with the Company’s Chairman and Chief Executive Officer, Mr. Stephen Van Deventer (the “Lender”).
Read more

PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that the Company’s research team at the University of Queensland has been granted the necessary approvals from a local hospital’s Human Ethics Committee to acquire and use human nasal mucosal tissue (mucosal membrane) for the final phase of the cannabinoid-based, soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”).
Read more

PreveCeutical Partnership Leads to Two New Patent Filings

April 17, 2019 PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H) announces that the Company’s research collaboration with UniQuest and The University of Queensland (“UQ”) has led to the filing of two new patent applications for cyclic peptides and their use in pain management (the “Patent Applications”).
Read more

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program

April 15th, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces the Company’s research team at the University of Queensland has filed an application to a local hospital’s Human Ethics Committee (the “Human Ethics Committee”) to acquire human nasal mucosal tissue (mucosal membrane) for use in the final phase of the cannabinoid-based, soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”).
Read more
Get $50 in free trades.